Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Belimumab | Benlysta | 4.4 Special Warnings and Special Precautions for Use | Available data do not support the safety and efficacy of concomitant use of BENLYSTA with rituximab | Feb,2023 |
| Asciminib | Scemblix | 4.5. Interactions with other medicinal products | Interaction with OATP1B and BCRP substrates, rosuvastatin and atorvastatin | Nov,2023 |
| Zanubrutinib | Itrazol | 4.3 Contraindications, 4.5. Interactions with other medicinal products | Co-administration of Cytochrome (CYP3A4) substrates is contraindicated with ITRAZOL | Nov,2023 |
| Warfarin Sodium | Coufatex | 4.5. Interactions with other medicinal products | Interactions with Ibrutinib. | Nov,2023 |
| Dabigatran Etexilate Mesylate | Pradaxa | 4.8 Undesirable effects | Multiple safety updates including: Anticoagulant-related nephropathy | Nov,2023 |
| Voriconazole | Vfend | 4.8 Undesirable effects | Phototoxicity and Periostitis (Update the frequency) | Nov,2023 |